Nalidixic AcidThird Party Manufacturing in India

Nalidixic Acid works by selectively inhibiting the A subunit of bacterial DNA gyrase. It inhibits DNA polymerization and replication forks to help the body eradicate susceptible Gram-negative urinary pathogens. Unlike systemic alternative classes, it concentrates rapidly within the urinary tract, acting as a site-specific anti-infective. It is highly effective and well-tolerated for uncomplicated urinary presentations. Sourced via compliant CAS 389-08-2 active streams, our partner plants verify crystal uniformity to ensure batch stability.

Celesta Healthcare offers manufacturing lines for Nalidixic Acid third party manufacturing in India, serving companies maintaining traditional antimicrobial options for specific clinical markets.

Therapeutic Uses

• Uncomplicated Urinary Tract Infections: Eradicates localized E. coli and Proteus infections within the bladder.
• Bacillary Dysentery: Controls specific Gram-negative bacterial overgrowth in the intestinal tract.

Why Manufacturers Choose Nalidixic Acid

This first-generation quinolone occupies a stable niche in specialized therapeutic and institutional lines under CAS 389-08-2. Our production facilities are WHO-GMP certified, ensuring that each solid oral dose undergoes strict identity testing and consistent quality verification before leaving the depot.